Prognostic Factors in Patients with Prostate Cancer Refractory to Endocrine Therapy: Univariate and Multivariate Analyses Including Doubling Times of Prostate-specific Antigen and Prostatic Acid Phosphatase

Japanese Journal of Clinical Oncology

Volumn 27, Issue 4, 1997, Pages 258-262

  Akimoto, Susumu ^a,b   Inomiya, Hideji ^a   Akakura, Koichiro ^a   Shimazaki, Jun ^a   Ito, Haruo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Prognostic factors; Prostate cancer; Prostate specific antigen; Prostatic acid phosphatase; Refractory to endocrine therapy

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CHLORMADINONE ACETATE; CISPLATIN; DRUG DERIVATIVE; ESTROGEN; GONADORELIN; IMIDAZOLE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE; LACTIC ACID DERIVATIVE; NILUTAMIDE; PROGESTERONE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; DISEASE COURSE; ENZYMOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORCHIECTOMY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ACID PHOSPHATASE; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORMADINONE ACETATE; CISPLATIN; DISEASE PROGRESSION; ESTROGENS; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; KARNOFSKY PERFORMANCE STATUS; LACTATES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROGESTERONE CONGENERS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031205657     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/27.4.258     Document Type: Article

References (23)

1. Catalona WJ, Scott WW. Carcinoma of the prostate In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, editors. Campbell's Urology, 5th ed.Philadelphia: WB Saunders 1986:1510.
2. Berry WR, Laszlo J, Cox E, Walker A, Paulson D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 1979;44:763-75.
3. DeWys WD, Begg C, Brodovsky H, Creech R, Khandekar J. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostate cancer: prognostic factors. Prostate 1983;4:1-11.
4. Emrich LJ, Priore RL, Murphy GP, Brady MF, the Investigators of the National Prostatic Cancer Project. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985,45:5173-9.
5. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A et al. Androgen priming and chemotherapy in advanced prostate cancer, evaluation of determinants of clinical outcome. J Clin Oncol 1988;6:1456-66
6. Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 1992;70:2870-8.
7. Fossa SD, Deamaley DP, Law M, Gad J, Newling DWW, Tveter K. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 1992;3:361-6.
8. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11:607-15.
9. Akimoto S, Masai M, Akakura K, Shimazaki J Tumor marker doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 1995;27:207-12.
10. Catalona WJ, Scott WW. Carcinoma of the prostate. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, editors. Campbell's Urology, 5th ed.Philadelphia: WB Saunders 1986;1480-1.
11. Gleason DF and The Veterans Administration Cooperative Urological Research Group. Histologic Grading and Clinical Staging of Prostatic Carcinoma. In: Tannebaum M. editor.Urologic Pathology: The Prostate. Philadelphia: Lea & Febiger 1977:171-98.
12. Akimoto S, Akakura K, Ohki T, Shimazaki J, Kuriyama M, Kawada Y. Usefulness of hyper sensitive PSA assay kits for determination on low range of prostate specific antigen in prostate cancer Nippon Hinyokika Gakkai Zasshi 1995;86:256-62 (in Japanese).
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
14. Oosterom R, Leijnse B, Bogdanowicz J, Schroeder F H. Evaluation of an enzyme-immunoassay for prostatic acid phosphatase utilizing monoclonal antibodies. World J Urol 1986;4:153-8.
15. Kuriyama M, Akimoto S, Akaza H, Arai Y, Usami M, Imai K, et al. Comparison of various assay systems of prostate-specific antigen for standardization. Jpn J Clin Oncol 1992;22:393-9.
16. Lepor H, Kimball AW, Walsh PC. Cause-specific actuarial survival analysis:A useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol 1989;141:82-4.
17. SAS/STAT User's Guide. Release 6.03 Edition. Gary, North Carolina: SAS Institute Inc 1988:359-650.
18. Taylor CD, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993;11:2167-72.
19. Hussain M, Wolf M, Marshall E, Crawford D, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A southwest oncology group report. J Clin Oncol 1994;12:1868-75.
20. Yagoda AY, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant cancer. Cancer 1993;71:1098-109.
21. Akimoto S, Ohki T, Akakura K, Masai M, Shimazaki J. Chemotherapy for endocrine-therapy-refractory prostate cancer. Cancer Chemother Pharmacol 1994;35(suppl):S18-S22.
22. Visakorpi T, Kallioniemi OP, Koivula T, Isola J. New prognostic factors in prostatic carcinoma. Eur Urol 1993;24:438-449.
23. Gibbons RP. Prostate cancer:Chemotherapy. Cancer 1987;60:586-8.